Comment on “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women”

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women Yoshino et al . (Reports, 11 June 2021, p. 1224) have reported that nicotinamide mononucleotide (NMN) increases muscle insulin sensitivity in prediabetic women. However, the 13 women who received NMN had hepatic lipid content of 6.3 ± 1.2%, whereas the 12 in the placebo group had 14.8 ± 2.0% ( P = 0.003). Given that a target of NMN is liver fat clearance, this was not an effectively randomized trial.